Endpoints News

Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate

Published

2 weeks ago

on

With its blockbuster drug Xolair set to face biosimilar competition, Novartis said it will pay up to $2 billion in upfront and certain milestone payments to take Excellergy and its IgE …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version